These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 19417698

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B.
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
    Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N.
    Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Vigabatrin and epilepsy: lessons learned.
    Wild JM, Ahn HS, Baulac M, Bursztyn J, Chiron C, Gandolfo E, Safran AB, Schiefer U, Perucca E.
    Epilepsia; 2007 Jul; 48(7):1318-27. PubMed ID: 17635558
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L, Sæter M, Mørch-Johnsen GH, Hoff JM, Gajda A, Brodtkorb E, Midelfart A.
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [Abstract] [Full Text] [Related]

  • 12. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD, Tocher K, Acheson JF.
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Vigabatrin and alterations of the visual field].
    Argumosa A, Herranz JL, Arteaga R, Barrasa J, Calles L, Armijo J.
    Rev Neurol; 2002 Sep; 28(8):741-5. PubMed ID: 10363313
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M, Cubbidge RP, Hosking SL.
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.